Status:
COMPLETED
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
Lead Sponsor:
Medical University of Graz
Conditions:
COVID
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
We hypothesize that the intake of Omni-Biotic® 10 AAD can reduce intestinal inflammation and improves dysbiosis in Covid-19 disease. We further hypothesize that Omni-Biotic® 10 AAD can reduce the dura...
Detailed Description
The outbreak of the novel coronavirus (SARS-CoV-2)-infected disease (COVID-19) began in Wuhan, Hubei province in December 2019, spread throughout China in early 2020 and developed as a pandemic therea...
Eligibility Criteria
Inclusion
- Inclusion criteria
- 18 years or older
- Covid-19 infection diagnosed by a positive SARS-Cov-2 PCR (Polymerase chain reaction) result from a nasopharyngeal swab
- Informed (tele)consent Exclusion criteria
- Pre-existing diarrhoea (including but not restricted to chronic inflammatory bowel disease, chronic diarrhea of other causes, acute diarrheal illness -4 to -1 week before inclusion)
- Antibiotic therapy -4 to -1 week before inclusion
- Probiotic treatment -4 to -1 week before inclusion
- Technical difficulties to perform telemedicine study visits
Exclusion
Key Trial Info
Start Date :
September 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04420676
Start Date
September 24 2020
End Date
December 31 2024
Last Update
March 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine, Medical University of Graz
Graz, Austria, 8010